Aerosolized pentamidine failure rate
Executive Summary
Is 13% on currently recommended dose schedule of 300 mg over four weeks for prophylaxis and treatment of HIV-related Pneumocystic carinii pneumonia, Henry Masur, chief of clinical medicine at NIH's Clinical Center, reported May 7. Longer term studies are showing 20-25% failure rates for the drug, Masur said.